Keryx Biopharmaceuticals specializes in acquiring, developing and commercializing medically important pharmaceutical products to treat renal disease. The company is developing Zerenex (ferric citrate), which is an oral, ferric iron-based compound with the capability of binding to phosphate and forming non-absorbable complexes. Zerenex has completed a Phase 3 clinical trial in the U.S. for treating hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. For more information, visit the company’s Web site: http://www.keryx.com
Let us hear your thoughts below: